FINEARTS-HF Design Paper
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial
FINEARTS-HF Gamified Intervention to Enhance Enrollment
Gamified Behavioral Science Intervention to Enhance Trial Enrollment: An Embedded Study Within the FINEARTS-HF Trial
MRA in heart failure: A Meta-analysis
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
Spectrum of Kidney Risk in the FINEARTS-HF
Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure
FINEARTS-HF Time to Benefit
Time to Significant Benefit of Finerenone in Patients With Heart Failure
FINEARTS-HF SGLT2i-Background
Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure
FINEARTS-HF Age
Finerenone Improves Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF
FINEARTS Kidney Outcomes
Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial
FINEARTS-HF Baseline Paper
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial
FINEARTS-HF Primary Publication
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The access to the publication on NEJM has been sponsored by Bayer
FINEHEART
Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes
FINEARTS-HF Patients With Recent Worsening HF
Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial
FINEARTS-HF Lifetime Benefit
Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
FINEARTS-HF Effect according to LVEF
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial
FINEARTS-HF KCCQ
Effect of finerenone on the KCCQ in patients with HFmrEF/HFpEF: A prespecified analysis of FINEARTS-HF
